Targeting alpha-4 integrin with natalizumab for intermediate uveitis associated with multiple sclerosis.

Area of Science:

• Ophthalmology
• Neurology
• Immunology

Background:

• Intermediate uveitis (IU) and multiple sclerosis (MS) may share underlying pathogenic mechanisms.
• Ocular inflammation in MS can manifest as IU, often requiring systemic immunosuppression.

Purpose of the Study:

• To investigate the efficacy of natalizumab in treating intermediate uveitis associated with radiologically isolated multiple sclerosis.
• To evaluate natalizumab as a targeted therapy for MS-associated uveitis.

Main Methods:

• Case series of two patients with bilateral IU and radiologically isolated MS.
• Patients initially treated with corticosteroids and methotrexate without full disease control.
• Treatment switched to natalizumab monotherapy.

Main Results:

• Both patients achieved rapid and sustained resolution of uveitis following natalizumab treatment.
• Natalizumab enabled discontinuation of other immunosuppressive therapies.
• No clinical demyelination was present at the time of diagnosis of MS.

Conclusions:

• Natalizumab is effective in treating MS-associated uveitis, even in the absence of clinically evident MS.
• Targeting alpha-4 integrins with natalizumab offers a high-efficacy treatment option for MS-associated uveitis.
• This approach may allow for reduced overall immunosuppression.